Arkolith/Insider Trading/CUE/Form 4

Lin Shao-Lee

Chief Executive Officer, DirectorCue Biopharma, Inc. (CUE) · full profile →Form 4 · filed Aug 15, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.6M
Net Open-Market Flow
-$1.6M
Transactions
7
6 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 13, 2026Sell(S)5K$27.19$147K719K
Aug 13, 2026Sell(S)2K$28.11$67K716K
Aug 13, 2026Sell(S)10K$29.48$308K706K
Aug 12, 2026Option exercise(M)109K—$0764K
Aug 12, 2026Sell(S)34K$26.99$924K730K
Aug 12, 2026Sell(S)6K$27.75$160K724K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 12, 2026Option exercise(M)109K—$0218K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001725092-26-000013) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Cue Biopharma, Inc.

Build

Ask your agent about CUE insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001725092-26-000013"
Ask your agent
Use Arkolith to summarize insider buying and selling at Cue Biopharma, Inc.
over the last 90 days and cite the filings.